Mathilde Hunault-Berger
University of Angers
Internal medicineSurgeryPathologyOncologyUnivariate analysisRetrospective cohort studyHematologyImmunologyInduction chemotherapyChemotherapyHematopoietic stem cell transplantationCytarabineLeukemiaMyeloid leukemiaRegimenTransplantationIncidence (epidemiology)RefractoryCancer researchMedicineBiologyGastroenterology
88Publications
16H-index
1,537Citations
Publications 93
Newest
#1Damien Luque Paz (University of Angers)H-Index: 9
#2Laurane Cottin (University of Angers)H-Index: 5
Last. Barbara BurroniH-Index: 9
view all 14 authors...
Source
#1Raynier DevillierH-Index: 21
#2Edouard ForcadeH-Index: 15
Last. Pierre PeterlinH-Index: 15
view all 19 authors...
Abstract null null The benefit of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) for acute myeloid leukemia (AML) patients over 60 years remains a matter of debate, notably when performed in first complete remission (CR1). In order to clarify this issue, the French Innovative Leukemia Organization (FILO) performed a 10-year real-world time-dependent analysis. The study enrolled patients between 60 and 70 years of age with AML in CR1 after intensive chemotherapy with intermediate ...
Source
#1Stéphane de Botton (Institut Gustave Roussy)H-Index: 53
#2Joseph Brandwein (U of A: University of Alberta)H-Index: 29
Last. Mathilde Hunault-BergerH-Index: 16
view all 21 authors...
BACKGROUND The present study evaluated the relative survival benefits associated with enasidenib and current standard of care (SoC) therapies for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoietic stem cell transplantation (HSCT). METHODS Propensity score matching (PSM) analysis compared survival outcomes observed with enasidenib 100 mg daily in the phase I/II AG221-C-001 trial and SoC outcom...
Source
#1Sandrine Lemoine (University of Angers)
#2Maxime Renard (University of Angers)H-Index: 2
Last. Damien Luque Paz (University of Angers)H-Index: 9
view all 10 authors...
Source
#2Corentin Orvain (University of Angers)H-Index: 7
Diffuse large B-cell lymphoma (DLBCL) with extra nodal skeletal involvement is rare. It is currently unclear whether these lymphomas should be treated in the same manner as those without skeletal involvement. We retrospectively analyzed the impact of combining high-dose methotrexate (HD-MTX) with an anthracycline-based regimen and rituximab as first-line treatment in a cohort of 93 patients with DLBCL and skeletal involvement with long follow-up. Fifty patients (54%) received upfront HD-MTX for ...
Source
#1Anne Bouvier (University of Angers)H-Index: 1
#2Jean-François Hamel (University of Angers)H-Index: 10
view all 40 authors...
In this randomized phase 3 study, the FILO group tested whether the addition of 6 mg/m2 of gemtuzumab ozogamycin (GO) to standard chemotherapy could improve outcome of younger patients with de novo acute myeloid leukemia (AML) and intermediate-risk cytogenetics. GO arm was prematurely closed after 254 inclusions because of toxicity. A similar complete remission rate was observed in both arms. Neither event-free survival nor overall survival were improved by GO in younger AML patients (<60 years)...
Source
#1Sylvie Tondeur (French Institute of Health and Medical Research)H-Index: 5
#2Franciane PaulH-Index: 3
Last. Damien Luque PazH-Index: 9
view all 25 authors...
Source
No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 pa...
Source
Quizartinib improved outcome compared to chemotherapy in the QuANTUM-R study (median overall survival (OS): 6.2 months for quizartinib vs. 4.7 in the chemotherapy group; hazard ratio 0.76, p = 0.02...
Source
#2Sylvie FrançoisH-Index: 8
Last. Mathilde Hunault-BergerH-Index: 16
view all 11 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.